At Virginia Commonwealth University (VCU) Health System, hematopoietic cell transplant (HCT) patients receive proton pump inhibitors (PPI) during their admission to prevent chemotherapyinduced gastroduodenal injury. Before 2012, most patients were also discharged on PPI therapy to reduce the frequency of ulcers and upper gastrointestinal (GI) symptoms after HCT.
Although there is limited evidence with regard to acidsuppressive therapy post HCT, an international survey of HCT programs demonstrated that 11 of 27 (41%) responders discharged their patients on acid-suppressive therapy, specifically PPIs in eight institutions (personal communication to Mandy Gatesman). In most cases, there was no defined duration of therapy, which is not surprising given the paucity of data. In general, clinicians treating HCT patients have little guidance with regard to appropriate acid-suppressive agent, duration of therapy and whether prophylaxis is even warranted post discharge.
Adverse effects of PPI therapy may include magnesium deficiency, 1,2 increases in Clostridium difficile infection 3 and an increased risk of community-acquired pneumonia. 4 Compared with PPI therapy, H-2 receptor antagonists (H2RAs) have less pronounced and prolonged acid suppression that contributes to an advantageous side effect profile. Although H2RAs are not as effective as PPIs in preventing gastroduodenal injury caused by chemotherapy, they have been shown to be effective in reducing the frequency of ulcers and upper GI symptoms post chemotherapy. 5 As HCT patients are subject to low electrolyte levels 6 and increased risks of infection at baseline, a new practice was implemented at our institution whereby all patients were discharged on a H2RA unless a prior indication existed for a PPI. Following this practice change, we sought to determine the association between PPI use and electrolyte repletion and infection rates, and whether the use of H2RA was associated with reduced risk of these complications. To our knowledge, this is the first study to characterize the safety and effectiveness of acid-suppressive therapy post-HCT admission.
A retrospective, matched cohort study was conducted from 30 September 2010 through 31 March 2013. Patients 18 years or older receiving H2RA therapy post-HCT admission were matched by transplant type and preparatory regimen with patients receiving PPI. Matched pairs were evaluated for 4 weeks post discharge. Patients with baseline renal dysfunction (defined as a serum creatinine >2 mg/dL) and patients with a prior indication for PPI therapy were excluded. In addition to baseline characteristics, data collected included the amount and frequency of electrolyte repletion via a standard institutional protocol (4 g of i.v. magnesium sulfate for serum magnesium concentrations o 1.2 mg/dL; 2 g for concentrations 1.2-1.7 mg/dL), rates of infection (positive cultures, use of antibiotics, radiologic evidence of pneumonia) and patient-reported GI symptoms. Medications and medical conditions with the potential to affect electrolyte levels were also recorded and analyzed. Data were analyzed with descriptive statistics, paired t-tests and McNemar's Chi-square test. The study received approval from the Massey Cancer Center and VCU Institutional Review Board.
Thirty-two patients receiving H2RA post-HCT admission met inclusion criteria. Six patients changed to a PPI during the study period and were subsequently analyzed with regards to GI effectiveness only. The remaining 26 patients were matched by transplant type and preparatory regimens with HCT patients who received PPI therapy post discharge. Twenty-six matched pairs were included in the complete analysis.
There were no significant differences between groups with regard to age, gender or race (Table 1) . Twenty-six patients were allogeneic recipients with the majority receiving unrelated donor transplants with reduced-intensity preparatory regimens. Patients receiving PPIs post discharge required significantly more magnesium repletion in weeks 1, 3 and 4 post discharge (Table 2) . During weeks 1, 3 and 4, significantly more patients receiving H2RA therapy went an entire week without repletion vs patients receiving PPI therapy (Table 2 ). Although the magnitude or frequency of potassium or calcium repletion was generally higher among PPI users, these differences were not statistically significant. There were no differences between groups with respect to medications or medical conditions that may have contributed to electrolyte disturbances.
The number of patients with evidence of infection was not significantly different between groups. Only one patient was positive for C. difficile. At the time of C. difficile diagnosis, this patient was receiving esomeprazole 40 mg PO daily with ceftriaxone 2 g i.v. daily for suspicion of pneumonia. Three patients who received a PPI during the study period developed pneumonia vs one patient who received a H2RA (P = 0.6). There were no differences in the number of patients receiving antibiotics or the types of antibiotics between groups.
Compared with patients on H2RA therapy, significantly more patients receiving a PPI reported GI symptoms (30.8% vs 65.4%, P = 0.049), including nausea (34.4% vs 53.1%), vomiting (12.5% vs 25.0%), diarrhea (9.4% vs 12.5%) and gastritis (6.3% vs 9.4%). There were no significant differences regarding the type of GI symptoms reported. During the study period, 19% of patients receiving H2RA therapy changed to a PPI. Two patients were discharged on a PPI following an inpatient admission and six patients began PPI therapy due to inadequately controlled GI symptoms.
The mechanism of PPI-induced hypomagnesemia is not fully understood. Previous investigators have theorized that PPIs may interfere with the intestinal absorption of magnesium. 7 Others have proposed that increased intestinal loss of magnesium is a universal effect of chronic PPI therapy and magnesium homeostasis may only be disrupted in individuals who are unable to compensate by reducing renal tubular loss. 8 Various chemotherapy agents and cancers are also known to affect electrolyte levels, so the need for electrolyte repletion in a HCT population may be multifactorial.
9,10 By matching our two populations by transplant type and preparatory regimen, we attempted to reduce the variation in chemotherapy agents received and underlying disease states that may affect electrolyte levels. 9, 10 We also found that the use of diuretics and other medications affecting electrolyte levels were not significantly different between groups, therefore it is quite likely the difference in magnesium repletion in our study was due to the difference in the acid-suppressive agent used.
We also did not detect any significant differences in the infection rates between patients receiving PPI therapy vs H2RA therapy. However, three patients on PPI therapy developed pneumonia vs only one patient on H2RA therapy. The only case of C. difficile occurred in a patient receiving a PPI. Meaningful differences in infection rates may be detected in a larger sample size.
Our study was limited by its retrospective analysis, limitations in the medical record to correlate PPI doses with outcomes and the use of parametric statistics in this relatively small sample. To address the statistical limitations, all comparisons for the magnitude of electrolyte replacement were reexamined with a nonparametric approach using the Wilcoxon signed rank test. The only difference from the parametric analysis was the magnitude of potassium repletion at week 1 where the difference was significant (P = 0.031).
Unfortunately, there is very little published information regarding acid-suppressive therapy following discharge from HCT and many questions still remain. More robust evaluations need to be done to determine the appropriate duration of use or whether acid-suppressive therapy is even warranted at discharge for HCT patients. In addition to the adverse effects previously addressed, the use of acid-suppressive therapy may cause further challenges associated with cost, pill burden and potential for drug interactions, specifically for drugs that require an acidic environment for absorption. Further studies are needed to fully characterize the use and consequences of acid-suppressive therapy in this patient population.
This retrospective study evaluated the safety and effectiveness of acid-suppressive therapy post HCT. Compared with PPI therapy, the use of H2RA therapy post HCT was associated with a decrease in the magnitude and frequency of magnesium repletion with no effect on GI symptoms. The potential impact of this study is important because the number and duration of clinic visits post-HCT discharge are often related to the need for electrolyte repletion.
In conclusion, further studies are needed to elucidate the role of acid-suppressive therapy post-HCT discharge. On the basis of the data presented here, if acid-suppressive therapy is to be used, H2RA therapy deserves serious consideration in place of PPI, when possible, for HCT patients post discharge. Letter to the Editor
